SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Hope for new psoriasis treatment
Fri October 30th - A possible new therapy for psoriasis has shown promise, a European conference has heard. More
Shop workers' risk of getting COVID-19
Fri October 30th - Customer-facing shop staff are about five times more likely to test positive for COVID-19 than their colleagues in other positions, a small American study has found. More
CA125 test better at predicting ovarian cancer
Fri October 30th - A readily available blood test is able to predict ovarian cancer risk more successfully than previously thought – particularly for the over 50s, according to newly published findings. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Combination treatment could attack aggressive prostate cancers

Tuesday September 22nd 2020

An experimental cancer drug combined with targeted hormone treatment could treat an aggressive group of prostate cancers, a European conference has heard.

Delegates at the 2020 European Society for Medical Oncology (ESMO) meeting heard that the precision drug ipatasertib alongside abiraterone enabled some men with prostate cancer to live longer before their cancer worsened than those on abiraterone alone.

Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust found that the drug combination stopped the growth a group of cancers that lack a functioning PTEN gene and often rely on AKT, which results in a more aggressive form of the disease.

They say the results from the IPATential150 study could represent a significant advance for men with this form of the disease.

The team assessed the efficacy and safety of ipatasertib with abiraterone in men with advanced prostate cancer who had received no prior treatment.

Out of 1,101 study participants, 521 lacked a fully functioning PTEN gene and each patient was given steroids as well as either abiraterone and ipatasertib or abiraterone and a dummy pill.

The researchers found that ipatasertib plus abiraterone as a first-line treatment enabled men with prostate cancer whose tumours lacked a functioning PTEN gene to live longer before their disease progressed, compared with abiraterone alone.

The risk of tumour progression was reduced by 23% in men treated with ipatasertib plus abiraterone, compared with those on abiraterone alone and the study found that the ipatasertib combination achieved a three-fold increase in complete remissions and about a 20% increase in partial remissions.

The researchers showed that targeting both androgens and AKT signalling together could cut off cancer’s evolutionary escape routes and stop the growth of aggressive cancers.

They describe the initial data as promising, but they point out that overall survival data will require further follow-up.

Study leader Professor Johann de Bono, professor of experimental cancer medicine at The Institute of Cancer Research, London, and consultant medical oncologist at The Royal Marsden NHS Foundation Trust, said: "Targeting hormonal signals with drugs like abiraterone is highly effective in prostate cancer, but we know that tumours can eventually evade the effects of treatment by becoming reliant on other growth signals.

“Our new trial shows that we can treat some men with aggressive cancers even more effectively if we block both growth signals at once by combining abiraterone with a new precision medicine, ipatasertib.

“We found that the new combination treatment could extend the time before the cancer progressed in men whose tumours lacked a functioning PTEN gene. PTEN is one of the most commonly deleted genes in prostate cancer, and as a result men often have a particularly poor prognosis, so it is great news that this study could open up a new precision medicine approach for these patients.”

Tags: Cancer | Europe | Men's Health | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES